- Oops!Something went wrong.Please try again later.
Selecta Biosciences (NASDAQ: SELB) shares are trading higher on Wednesday potentially after its director Timothy Springer reported the purchase of 1,887,696 shares at an average price of $2.30 in a Form 4 filing in Tuesday's after hours.
Selecta Biosciences is a clinical-stage biopharmaceutical company. The company is engaged in using synthetic vaccine particle or SVP technology to discover and develop targeted therapies to modulate the immune system effectively and safely treat rare and serious diseases. It provides SVP for immune tolerance and stimulation.
The company products in Phase 1 and Phase 2 include SEL-403 for Pancreatic Cancer and Mesothelioma, SEL-212 for Chronic Severe Gout, SEL-302 for Methylmalonic Acidemia (MMA) and SEL-313 for Ornithine Transcarbamylase Deficiency (OTC).
Selecta Biosciences shares traded up 11.01% to $2.42 on Wednesday at the time of publication. The stock has a 52-week high of $4.83 and a 52-week low of $1.28.
See more from Benzinga
© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.